ICAM5 and bladder transitional cell carcinoma: We found that BLCA patients categorized into the UCHL5 high-expression group showed significantly higher c-Myc (Figure S1G, p < 0.001), SLC25A19 (Figure S1I, p < 0.001), and ICAM5 (Figure S1K, p < 0.05) expression levels compared with BLCA patients in the UCHL5 low-expression group.